GLP-1, Syngene & A $20 Billion Dream: Kiran Mazumdar-Shaw Reveals Biocon's Roadmap

By NDTV Profit

Community Score: 50% | 102 views | 1d

0 community ratings: null thumbs up, null thumbs down

Biocon is entering what could be its most important phase yet. In this exclusive conversation, NDTV Profit's Nisha Poddar talks to Biocon Founder & Executive Chairperson Kiran Mazumdar-Shaw at the company's Bengaluru campus to discuss the next chapter of India's leading biotechnology company. From the ambitious goal of building a $20 billion company to the global GLP-1 opportunity, insulin expansion, biosimilars, Singene's turnaround strategy, debt reduction, free cash flow, succession planning, and India's biotech innovation ecosystem—Kiran Mazumdar-Shaw shares her vision for the future in a wide-ranging interview. #biocon #kiranmazumdarshaw #stockmarket #biotech #glp For more videos subscribe to our channel: https://www.youtube.com/@NDTVProfitIndia Visit NDTV Profit for more news: https://www.ndtvprofit.com/ Don't enter the stock market unaware. Read all Research Reports here: https://www.ndtvprofit.com/research-reports Follow NDTV Profit here Twitter: https://twitter.com/NDTVP

Tags: ndtv profit, stock market, stock market news, stock market india, stock market today, today stock market news, share market live, share market live today, share market news live, today share market news, top stocks in focus, top stocks to buy, nifty live, union budget news, finance news, latest finance news, business news, latest business news, business news today, producer = somesh